Q1 2022 Results slide image

Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Oncology: Solid Tumors 88 Investor Relations | Q1 2022 Results Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health NOVARTIS | Reimagining Medicine
View entire presentation